The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Mechanisms of acquired resistance to TRK inhibitors.
 
Guilherme Harada
Speakers' Bureau - AstraZeneca; MSD; Pfizer
 
Noura J. Choudhury
Honoraria - MJH Life Sciences
Patents, Royalties, Other Intellectual Property - Royalties from Wolters Kluwer (Pocket Oncology).
 
Alison M. Schram
Consulting or Advisory Role - Mersana
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Kura Oncology (Inst); Lilly (Inst); Merus (Inst); Northern Biologics (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Surface Oncology (Inst)
 
Ezra Rosen
No Relationships to Disclose
 
Yonina R. Murciano-Goroff
Honoraria - Virology Education
Research Funding - Elucida Oncology (Inst); Loxo/Lilly (Inst); Taiho Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Christina J. Falcon
No Relationships to Disclose
 
Clare Wilhelm
No Relationships to Disclose
 
Lauren A. Kaplanis
No Relationships to Disclose
 
Dazhi Liu
Consulting or Advisory Role - InVitae
 
Jason C. Chang
No Relationships to Disclose
 
Soo-Ryum Yang
No Relationships to Disclose
 
Aradhika Dhawan
No Relationships to Disclose
 
Patrick Evans
No Relationships to Disclose
 
Casey Savin
No Relationships to Disclose
 
Grace Grimaldi
No Relationships to Disclose
 
Ronak H. Shah
Stock and Other Ownership Interests - 10X Genomics; AstraZeneca/MedImmune; Guardant Health; Regeneron; Roche
 
Emiliano Cocco
No Relationships to Disclose
 
Alexander E. Drilon
Stock and Other Ownership Interests - Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV More; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva